DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics’ cell isolation and manufacturing process is protected globally by 30 issued patents and 29 additional patents pending, and is trade secret protected.